Triazolyl phenyl benzenesulfonamides
US8153818B2 · kind B2 · utility
3Cited by
3References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 2, 2010 |
| Grant date | Apr 10, 2012 |
| Priority date | — |
| Expiry date | Apr 2, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.